aq b12 injection Compounded Hydroxocobalamin (Vitamin B12) blood formation B 29 AQ PFS 1500mcg

Depending on the severity and the progression of the neuropathy, muscle atrophy also occurs

They optimise one specific metabolic pathway

Phase 2 and Phase 3 trial data Major clinical trials: Phase 2 (24-week trial, 2008): 203 obese participants Three dose groups: 0.25mg, 0.5mg, 1.0mg daily Placebo-controlled, randomized Primary outcome: Weight loss percentage Phase 2 results: Key findings: Dose-dependent weight loss 1mg dose: Average 23 lbs lost (starting weight ~220 lbs) Best responders: 15-20% weight loss Comparable to semaglutide 2.4mg But higher dropout due to side effects Phase 3 trials (planned but never completed): Intended for FDA approval Halted due to cardiovascular concerns Increased heart rate 5-10 bpm average Blood pressure elevation 2-5 mmHg Risk-benefit ratio questioned Development suspended 2010 Long-term data (limited): 1-year extension studies showed sustained loss Weight plateau at 6-9 months Some regain if discontinued No controlled trials beyond 1 year Safety concerns prevented longer studies Compare to semaglutide trials and tirzepatide results

Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial

Drug/Laboratory Test Interactions Most antibiotics, methotrexate, and pyrimethamine invalidate folic acid and vitamin B12 diagnostic microbiological blood assays

It may also reduce appetite, promote muscle growth and healthy immune systems, and aid in fat metabolism and transport, making it easier for the body to break down undesirable fat storage